{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:23:00Z","timestamp":1791868980779,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41409-021-01288-9","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:04:32Z","timestamp":1629414272000},"page":"2911-2921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9443","authenticated-orcid":false,"given":"Pashna N.","family":"Munshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-6694","authenticated-orcid":false,"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-6707","authenticated-orcid":false,"given":"Mats","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmello","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"1288_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours, Revised 4th Edition, Volume 2.2. p. 215\u2013344."},{"key":"1288_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, Weil K, Furman R, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27:1209\u201313.","journal-title":"J Clin Oncol"},{"key":"1288_CR3","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. ESMO Guidelines Committee. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62\u2013iv71.","journal-title":"Ann Oncol"},{"key":"1288_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2014.223","volume":"29","author":"S Robinson","year":"2015","unstructured":"Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, et al. European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015;29:464\u201373.","journal-title":"Leukemia"},{"key":"1288_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132:1647\u201356.","journal-title":"Blood"},{"key":"1288_CR6","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen L, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903\u201310. https:\/\/doi.org\/10.1182\/blood-2017-04-779736.","journal-title":"Blood"},{"key":"1288_CR7","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M, R\u00e4ty R, Wader K, Laurellet A. al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109\u2013e116.","journal-title":"Lancet Haematol"},{"key":"1288_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","volume":"131","author":"SM Aukema","year":"2018","unstructured":"Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue M, Rymkiewicz G, et al. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL Network. Blood. 2018;131:417\u201320.","journal-title":"Blood"},{"key":"1288_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl B, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2013;369:507\u201316.","journal-title":"N. Engl J Med"},{"key":"1288_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"ML Wang","year":"2020","unstructured":"Wang ML, Munoz J, Goy A, Locke F, Jacobson C, Hill B, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2020;382:1331\u201342.","journal-title":"N. Engl J Med"},{"key":"1288_CR11","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, Gisselbrecht C, Schmits R, Metzneret B. al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677\u201384.","journal-title":"Blood"},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","volume":"32","author":"TS Fenske","year":"2014","unstructured":"Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns L, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273\u201381.","journal-title":"J Clin Oncol"},{"key":"1288_CR13","first-page":"43","volume":"37","author":"A Zoellner","year":"2019","unstructured":"Zoellner A, Unterhalt M, Stilgenbauer S, H\u00fcbel K, Thieblemont C, Metzner B, et al. Autologous stem cell transplantation in first remission significantly prolongs progression-free and overall survival in mantle cell lymphoma. Int Conf Malig Lymphoma, Hematological Oncol. 2019;37:43\u201344.","journal-title":"Int Conf Malig Lymphoma, Hematological Oncol"},{"key":"1288_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/JCO.18.00690","volume":"37","author":"JN Gerson","year":"2019","unstructured":"Gerson JN, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37:471\u201380.","journal-title":"J Clin Oncol"},{"key":"1288_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","volume":"119","author":"A LaCasce","year":"2012","unstructured":"LaCasce A, Vandergrift J, Rodriguez M, Abel G, Crosby A, Czuczman M, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119:2093\u20139.","journal-title":"Blood"},{"key":"1288_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009.","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn K, Carreras J, Cairo M, Fenske T, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2013;19:625\u201331. https:\/\/doi.org\/10.1016\/j.bbmt.2013.01.009.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00277-014-2087-z","volume":"93","author":"WH Kr\u00fcger","year":"2014","unstructured":"Kr\u00fcger WH, Hirt C, Basara N, Sayer H, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology\/Oncology (OSHO). Ann Hematol. 2014;93:1587\u201397.","journal-title":"Ann Hematol"},{"key":"1288_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N. Engl J Med. 2017;377:1250\u201360.","journal-title":"N. Engl J Med"},{"key":"1288_CR19","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.3747\/co.26.4345","volume":"26","author":"C Owen","year":"2019","unstructured":"Owen C, Berinstein NL, Christofides A, Sehn L. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26:e233\u2013e240. https:\/\/doi.org\/10.3747\/co.26.4345.","journal-title":"Curr Oncol"},{"key":"1288_CR20","first-page":"3136","volume":"30","author":"DA Loblaw","year":"2012","unstructured":"Loblaw DA, Prestrud A, Somerfield M, Oliver T, Brouwers M, Nam R, et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. Clin Oncol. 2012;30:3136\u201340.","journal-title":"Clin Oncol"},{"key":"1288_CR21","first-page":"i","volume":"2","author":"MK Murphy","year":"1998","unstructured":"Murphy MK, Black NA, Lamping DL, McKee CM, Sanderson CF, Askham J, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i\u2013iv.","journal-title":"Health Technol Assess"},{"key":"1288_CR22","doi-asserted-by":"publisher","first-page":"12100","DOI":"10.1200\/JCO.2013.54.0955","volume":"32","author":"N Ramakrishna","year":"2014","unstructured":"Ramakrishna N, Temin S, Chandarlapaty S, Crews J, Davidson N, Esteva F, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2\u2013positive breast cancer and brain metastases: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32:12100\u20138. https:\/\/doi.org\/10.1200\/JCO.2013.54.0955.","journal-title":"J Clin Oncol"},{"key":"1288_CR23","doi-asserted-by":"publisher","unstructured":"Berkman ND, Lohr KN, Ansari MT, Balk E, Kane R, McDonagh MS, et al. Grading the strength of a body of evidence when assessing health care interventions: An EPC update. J Clin Epidemiol. 2015;68:1312\u201324. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.11.023.","DOI":"10.1016\/j.jclinepi.2014.11.023"},{"key":"1288_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen N, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u2009+\u2009autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355\u201362. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09174.x.","journal-title":"Br J Haematol"},{"key":"1288_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2007.06908.x","volume":"140","author":"AM Evens","year":"2008","unstructured":"Evens AM, Winter JN, Hou N, Nelson B, Rademaker A, Patton D, et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: Long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008;140:385\u201393.","journal-title":"Br J Haematol"},{"key":"1288_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"1288_CR27","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/j.bbmt.2020.07.019","volume":"26","author":"S Chhabra","year":"2020","unstructured":"Chhabra S, Thapa B, Szabo A, Konings S, D\u2019Souza A, Dhakal B, et al. Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients. Biol Blood Marrow Transpl. 2020;26:2011\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.019.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1288_CR28","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon LE, Johnson JL, Niedzwiecki D, Cheson B, Hurd D, Bartlett N. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27:6101\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.22.2554.","journal-title":"J Clin Oncol"},{"key":"1288_CR29","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O, Kluin-Nelemans H, Walewski J, van Hoof A, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338\u201346.","journal-title":"J Clin Oncol"},{"key":"1288_CR30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","volume":"184","author":"RJ Lin","year":"2019","unstructured":"Lin RJ, Ho C, Hilden PD, Barker J, Giralt S, Hamlin P, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006\u201310.","journal-title":"Br J Haematol"},{"key":"1288_CR31","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M, Silva R, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770\u20138.","journal-title":"Lancet"},{"key":"1288_CR32","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407\u201312. https:\/\/doi.org\/10.1200\/JCO.2003.05.501.","journal-title":"J Clin Oncol"},{"key":"1288_CR33","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","volume":"104","author":"MB Maris","year":"2004","unstructured":"Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart M, Maziarz R, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535\u201342. https:\/\/doi.org\/10.1182\/blood-2004-06-2275.","journal-title":"Blood"},{"key":"1288_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040620710396752","volume":"2","author":"JG Cruz","year":"2011","unstructured":"Cruz JG, Martino R, Balsalobre P, Heras I, Pinana J, Serrano D, et al. Long-TErm Results of Fludarabine\/melphalan as A Reduced-intensity Conditioning Regimen in Mantle Cell Lymphoma: the GELTAMO experience. Ther Adv Hematol. 2011;2:5\u201310. https:\/\/doi.org\/10.1177\/2040620710396752.","journal-title":"Ther Adv Hematol"},{"key":"1288_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaoncol.2018.6278","volume":"5","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, et al. Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. JAMA Oncol. 2019;5:715\u201322. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6278.","journal-title":"JAMA Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01288-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:59:48Z","timestamp":1744167588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01288-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MH reports: Research Support\/Funding: Takeda Pharmaceutical Company; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: Janssen; Incyte Corporation; ADC Therapeutics; Celgene Corporation; Omeros, Verastem, MorphoSys. Speaker\u2019s Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. TSF reports: Research Support\/Funding: Novartis, Portola, Curis; Consultancy: Adaptive Biotechnologies, AbbVie, KaryoPharm, Kite, MorphoSys, Pharmacyclics, Sanofi. Speaker\u2019s Bureau: Sanofi, Seattle Genetics, AstraZeneca, Celgene\/ Bristol-Myers Squibb, Adaptive Biotechnologies. PNM reports: Speaker\u2019s Bureau: Kite, a Gilead Company, Incyte. JBC reports: Consulting\/Advisory Boards: Janssen, Adicet, BeiGene, Cellectar, Kite\/Gilead, Adaptive, Aptitude Health, Astra Zeneca, Loxo. Research Support\/Funding: Novartis, BMS\/Celgene, Takeda, Genentech, Astra Zeneca, Loxo, LAM, Atara, BeiGene. NG reports: Speakers Bureau: Kite Pharma, Astra Zeneca, AbbVie, Janssen, BMS, Epizyme; Consulting\/Advisory: Kite Pharma, Astra Zeneca, AbbVie, Janssen, BMS, Incyte, Epizyme, Karyopharma, Genmab, Adaptive Biotech, T.G. Therapeutics, ADC Therapeutics, BeiGene; Research funding: Genentech\/Roche, BMS, T.G. Therapeutics, Pharmacyclics, Kite Pharma. MK reports: Research Support\/Funding: TG Therapeutics, Genentech. Consultancy: AbbVie, KaryoPharm, Kite, AstraZeneca, Celgene\/ Bristol-Myers Squibb, Adaptive Biotechnologies, Curio Science. Speaker\u2019s bureau: SeaGen. MJ reports: Research Support\/Funding: Janssen, Celgene, Abbvie, Gilead, Roche, Consultancy: Janssen; Incyte; Gilead, Roche, Bristol-Myers Squibb; Acerta; BioInvent. JWF reports: DSMB activities: Bayer, Ascerta, Novartis. CCS reports: Research support\/Funding: ADC Therapeutics, Sanofi, Roche. Consulting\/Advisory: Sanofi, ADC Therapeutics, Roche, Karyopharm Therapeutics, Celgene\/Bristol-Myers Squibb, Incyte. Honoraria: Bristol-Myers Squibb, Janssen Oncology, AstraZeneca. Travel Grants: Roche, Janssen, Takeda, ADC Therapeutics. VB reports: Advisory Board: Kite, Gamida Cell: Research support\/Funding: Incyte, Gamida Cell, GT Biopharma. TP reports: Research Support\/Funding: Incyte, BMS\/Celgene, Bayer, Abbvie, Genentech; Consultancy: BMS, Bayer, Abbvie, Genentech, Gilead, Gilead\/Kite TG Therapeutics, ADC Therapeutics, Incyte, MrophoSys, BeiGene, AstraZenca, Epizyme. FLL reports: Research Support\/Funding: Kite, a Gilead Company; Scientific Advisor: Allogene, Amgen, Bluebird Bio, BMS\/Celgene, Calibr, Celgene, GammaDelta Therapeutics, Iovance, Kite\/Gilead, Legend Biotech, Novartis, Wugen; Consultancy: Cellular Biomedicine Group, Cowen Consulting, Gerson Lehrman Group (GLG), EcoR1, Emerging Therapies. BK reports: Research Support\/Funding: Abbvie, Acerta, AstraZeneca, Beigene, Celgene, Genentech; Consulting: Abbvie, Acerta, AstraZeneca, Beigene, Celgene, Kite, Genentech, Pharmacyclics, Janssen. MAKD reports: Consultancy: Pharmacyclics, Daiichi Sankyo. AFH reports: Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Seattle Genetics, Karyopharm, Genentech\/Roche; Research Funding: Bristol-Myers Squibb (Inst), Genentech\/Roche (Inst), Merck (Inst), Seattle Genetics (Inst), ADC Therapeutics (Inst), Gilead\/Kite Pharma (Inst); Travel, Accommodations, Expenses: Bristol-Myers Squibb. KJM reports: Research funding: Pharmacyclics, BMS, Merck, Novartis; Consultancy: Pharmacyclics, Janssen, Morphosys, Celgene, Beigene, Kite, Karyopharm, ADC Therapeutics, Seattle Genetics. VPK reports: Research funding: Novartis. DJI reports: Research funding: Acerta Pharma. CSS reports: Consultancy\/Advisory boards: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite\/a Gilead Company, Celgene\/BMS, Gamida Cell, Karyopharm Therapeutics, GSK; Research Funding: Juno Therapeutics, Celgene\/BMS, Bristol-Myers Squibb, Precision Biosciences and Sanofi-Genzyme. PD reports: consultancy for AbbVie, AstraZeneca, bluebird bio, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, Riemser, Roche; research support from Riemser. JPL reports: Research support: Leukemia & Lymphoma Society, Genentech Foundation. Consulting: Sutro, Miltenyi, AstraZeneca, Epizyme, BMS\/Celgene, Regeneron, Bayer, Gilead\/Kite, Karyopharm, GenMab, Genentech\/Roche, Abbvie, Incyte. MD reports: institutional research funding: Abbvie, Bayer, Celgene, Janssen, Roche. Advisory Boards: Astra Zeneca, Bayer, Beigene, Celgene, Genmab, Gilead, Incyte, Janssen, Novartis, Roche. Speaker\u2019s honoraria: Amgen, Astra Zeneca, Bayer, Celgene, Gilead, Janssen, Roche. BTH reports: research funding: Kite\/Gilead, Celgene\/BMS, Genentech, Pharmacyclics, Abbvie. Consulting: Kite\/Gilead, Celgene\/BMS, Novartis, Beigene, AstraZeneca, Genentech, Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}